IgA Nephropathy Treatment Market to Reach USD 3.24 Billion by 2033 | Novel Targeted Therapies, Complement & Endothelin Inhibitors Drive 18.1% CAGR

The IgA Nephropathy Treatment Market size reached USD 759.50 million in 2024 and is projected to reach USD 3,238.53 million by 2033, growing at a CAGR of 18.1% from 2025 to 2033. This robust growth is driven by the rising prevalence of IgA nephropathy worldwide, increasing diagnosis rates through improved screening, multiple novel drug approvals shifting from supportive care to targeted therapies, innovations in complement inhibitors and endothelin antagonists, a strong pipeline of biologics and immunosuppressants, and expanding access in emerging markets amid aging populations and chronic kidney disease burdens.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-
https://www.datamintelligence.com/download-sample/iga-nephropathy-treatment-market?sindhuri

North America: Key Industry Developments (Largest Region)
✅ November 2025: Otsuka Pharmaceutical (Visterra) received FDA accelerated approval for Voyxact (sibeprenlimab), an APRIL inhibitor demonstrating significant proteinuria reduction in high-risk IgA nephropathy patients.
✅ April 2025: Novartis secured FDA accelerated approval for Vanrafia (atrasentan), the first selective endothelin A receptor antagonist for reducing proteinuria in primary IgA nephropathy.
✅ August 2024: Novartis gained FDA accelerated approval for Fabhalta (iptacopan), marking the first complement inhibitor specifically for IgA nephropathy proteinuria reduction.

Asia Pacific: Key Industry Developments (Fastest Growing Region)
✅ December 2024: Japanese Ministry granted orphan drug designation to Sparsentan (Travere Therapeutics/Renalys Pharma), accelerating development for high-incidence markets.
✅ January 2025: Renalys Pharma completed enrollment in Phase III trials for Sparsentan in Japan, with results expected mid-2025 to support regional approval.
✅ Ongoing 2025: Expanding investments in targeted therapies and screening programs in China, India, and Japan to address rising prevalence and unmet needs in underserved populations.

Key Mergers and Acquisitions (2025):
✅ Travere Therapeutics expands global reach: Out-licensing of Sparsentan to CSL Vifor (Europe) and Renalys Pharma (Japan/Asia), strengthening commercialization of FILSPARI in key growth regions.
✅ Novartis bolsters kidney portfolio: Integration of atrasentan (Vanrafia) assets, enhancing leadership in complement and endothelin-targeted IgA nephropathy treatments.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=iga-nephropathy-treatment-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis:
-By Drug: ACE Inhibitors Lead with Dominant Share
The ACE Inhibitors segment commands the largest market share (34.5% in 2024), established as first-line therapy for blood pressure control, proteinuria reduction, and cardiovascular protection per KDIGO guidelines.
Angiotensin Receptor Blockers and emerging targeted therapies (e.g., DEARAs, complement inhibitors) are fastest-growing amid novel approvals.
-By Disease Type: Primary IgA Nephropathy Commands Largest Portion
Primary IgA Nephropathy dominates due to higher prevalence and focus of recent targeted drug developments.
-By Gender/Other: Balanced Demand with Focus on High-Risk Patients
Treatments increasingly tailored for patients with rapid progression risk (e.g., high proteinuria).

Growth Drivers:
Rising Prevalence and Improved Diagnosis → Increasing global incidence, especially in Asia, coupled with better screening drives early intervention.
Novel Targeted Therapy Approvals → Shift from supportive care to disease-modifying drugs like Fabhalta, FILSPARI, Vanrafia, and emerging biologics.
Strong Pipeline and R&D Investments → Late-stage candidates targeting complement, APRIL, and endothelin pathways promise further innovation.
Aging Population and Comorbidities → Higher chronic kidney disease burden amplifies demand for effective treatments.
Regulatory Support and Orphan Designations → Accelerated approvals and incentives fuel rapid market entry of new therapies.

Speak to Our Analyst and Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/iga-nephropathy-treatment-market?sindhuri

Regional Insights:
North America dominates the global IgA Nephropathy Treatment market, accounting for the largest share (44.8% in 2024). Leadership stems from high prevalence and diagnosis rates, advanced healthcare infrastructure, rapid adoption of novel therapies, multiple FDA approvals, and presence of key innovators.
Asia-Pacific is the fastest-growing region (projected CAGR of 19.1%), driven by high disease incidence (e.g., Japan), government investments, orphan designations, Phase III trials, and expanding access to targeted treatments.

Key Players:
Travere Therapeutics, Inc. | Calliditas Therapeutics AB | Novartis AG | STADA Arzneimittel | Everest Medicines | Viatris Inc. | Vertex Pharmaceuticals Incorporated | Otsuka Pharmaceutical Co., Ltd. | RemeGen | Vera Therapeutics

Key Highlights (Top 5 Key Players) for IgA Nephropathy Treatment Market:
1. Novartis AG leads with dual approvals for Fabhalta (iptacopan, complement inhibitor) and Vanrafia (atrasentan, endothelin antagonist), targeting multiple pathways for proteinuria reduction and disease modification.
2. Travere Therapeutics strengthens position via FILSPARI (sparsentan), the first DEARA with U.S./European approvals and Asian partnerships for global expansion.
3. Calliditas Therapeutics pioneered targeted therapy with TARPEYO (budesonide), the first approved gut-directed release formulation addressing mucosal immune dysregulation.
4. Otsuka Pharmaceutical (Visterra) advances with Voyxact (sibeprenlimab), an APRIL inhibitor offering significant proteinuria reduction in late-stage data.
5. RemeGen progresses pipeline with Telitacicept, a dual-target biologic in Phase III, targeting B-cell modulation for emerging markets.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.